Medical Sample 8

422 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
422
On SlideShare
0
From Embeds
0
Number of Embeds
23
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Medical Sample 8

  1. 1. Launch Status 2004 Oct… Dec 2005 Jan… Mar Apr May Jun Jul Aug Sept… Dec 2006 UK Netherlands Norway France Italy Japan Germany Sweden Spain Mexico Finland • Carefully monitoring launches and rapidly sharing learnings across geographies • Japan will launch with hypertension indication
  2. 2. EU Launches Leverage US Learnings Reach and 19 CHRs (80% time on 100 PHRs* 2 Hospital frequency Inspra) – Inspra 2 nd position teams – Experienced in 32 IHRs (covering > – Inspra 1st cardiology/hospitals 300 bed hospitals) position – 9 HF nurses – Inspra 1st position Early and HF nurses preparing Extensive AB plan Already on broad hospital patient care pathways and (1000 studies w/5000 nearly all access identifying advocates on patients – all in- hospital D&T committee hospital starts) formularies Urgency to Timing allowed addition of Could not be Launched with treat 30-day data, but it is not incorporated at launch new concept hospitalized the focus – updating the because no publication patient focus in next wave available – updating materials in next wave * Significant distraction due to Lipitor access issues.
  3. 3. Current Status • Communication platform refined to establish risk and urgency, focus on hospital initiation • Limited US FF reach and frequency continues to be a challenge • US Launch learnings incorporated into EU Launch plans – Representatives in Ex-US markets selling Inspra in 1st and 2nd position – France doing extensive pre-launch campaign to get on hospital formularies and protocols • Spironolactone comparison is a key issue during details (cost, MOA) • Pricing continues to be an issue in EU

×